Browne, P.V., Shalev, O., Kuypers, F.A., Brugnara, C., Solovey, A., Mohandas, N., Schrier, S.L. and Hebbel, R.P. (1997) Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassemia. Jour- nal of Clinical Investigation, 100, 1459-1464. doi:10.1172/JCI119666

has been cited by the following article:

• TITLE: Evaluation of a novel oral iron chelator 1-(N-acetyl-6-aminohexyl)-3-hydroxypyridin-4-one (CM1) for treatment of iron overload in mice

  AUTHORS: Somdet Srichairatanakool, Kanjana Pangjit, Chada Phisalaphong, Suthat Fucharoen

  KEYWORDS: Thalassemia; Iron Overload; Iron Chelator; Hydroxypyridinone; Lipid Peroxidation; Malondialdehyde

  JOURNAL NAME: Advances in Bioscience and Biotechnology, Vol.4 No.2, February 28, 2013

  ABSTRACT: Desferrioxamine (DFO), deferiprone (DFP) and deferasirox (DFX) are promising effective iron chelators for the treatment of iron overload in b-thalassemia patients; nonetheless, their side effects have also been reported. 3-Hydroxypyridinone derivatives are being developed as a safer new chelator and in combined chelation therapy. We evaluated the iron-chelating activity of 1-(N-acetyl-6-aminohexyl)-3-hydroxypyridin-4-one (CM1) in iron-loaded C57BL6 mice. The feeding of a ferrocene-supplemented diet (Fe diet) to mice resulted in iron overload, detectable plasma nontransferrin-bound iron (NTBI) and labile plasma iron (LPI), and increases of red cell membrane iron, plasma malondialdehyde (MDA) and excessive tissue iron deposits. Like DFP, the CM1 lowered the levels of the membrane non-heme iron, the NTBI and LPI (p